Maxine Gowen, Ph.D.
President and Chief Executive Officer
Dr. Gowen is the founding President and CEO of Trevena. Prior to this Dr. Gowen held a variety of leadership roles at GlaxoSmithKline (GSK) over a period of fifteen years. As Senior Vice President for the Center of Excellence for External Drug Discovery (CEEDD), she developed an innovative new approach to externalizing drug discovery in big pharma. Dr. Gowen was previously President and Managing Partner at SR One, the venture capital subsidiary of GSK, where she led its investments in and served on the board of directors of numerous companies. Until 2002 Dr. Gowen was Vice President, Drug Discovery, Musculoskeletal Diseases at GSK, responsible for drug discovery and early development for osteoporosis, arthritis and metastatic bone disease. Dr. Gowen held a tenured academic position in the School of Pharmacology, University of Bath, UK from 1989-1992. She has authored more than 100 refereed scientific publications. Dr. Gowen graduated with a B.Sc. in biochemistry from the University of Bristol, UK, then received a Ph.D. in cell biology from the University of Sheffield, UK, and received an MBA from the Wharton School of the University of Pennsylvania. Dr. Gowen served on the board of Human Genome Sciences (HGSI) until its purchase by GSK in July 2012. She currently serves on the board of Akebia Therapeutics, Inc. (AKBA) since July 2014 and Idera Pharmaceuticals, Inc. (IDRA) since January 2016, both public biopharmaceutical companies, and on the boards of the state and national biotechnology industry associations, Life Sciences PA and BIO, respectively.
Carrie L. Bourdow
Senior Vice President and Chief Commercial Officer
Ms. Bourdow joined Trevena as Senior Vice President and Chief Commercial Officer in May 2015. Most recently, she was vice president of marketing, reimbursement, and operations at Cubist Pharmaceuticals, Inc., where she led launch strategy, marketing, reimbursement, and operations for five acute care hospital pharmaceuticals totaling over $1 billion in annual revenues. Prior to joining Cubist in 2013, Ms. Bourdow served for more than 20 years at Merck & Co., Inc., where she held positions of increasing responsibility across several therapeutic areas including anti-infectives, acute heart failure, and pain. Ms. Bourdow has a B.A. degree from Hendrix College and earned her M.B.A. from Southern Illinois University. Since June 2017, she has served on the board of Nabriva Therapeutics plc., a publicly traded biopharmaceutical company.
Roberto Cuca, J.D.
Senior Vice President and Chief Financial Officer
Mr. Cuca joined our company as Senior Vice President and Chief Financial Officer in September 2013. Before this he held various leadership positions in the finance organization of Endo Health Solutions Inc., a pharmaceutical company, from March 2010 to August 2013, including, most recently, Treasurer and Senior Vice President, Finance. Prior to that, he was Director, Corporate and Business Development, at moksha8 Pharmaceuticals, Inc., an emerging markets focused pharmaceutical company, from March 2008 until February 2010. From 2005 until 2008, he worked at JPMorgan Chase & Co. as an equity analyst covering U.S. pharmaceutical companies. Mr. Cuca received an M.B.A. from the Wharton School of The University of Pennsylvania, a J.D. from Cornell Law School, an A.B. from Princeton University and he is a CFA charterholder.
Yacoub Habib, Ph.D.
Senior Vice President, Business Development and Corporate Planning
Dr. Habib joined Trevena in July 2015. Previously, he served as vice president of business development at Ikaria, Inc. and led the business development strategy for the company until its acquisition. From 2007 to 2009, he served as executive director of new business development for Pfizer and participated in the creation of new business development strategies in areas outside of Pfizer’s core competency markets. Before joining Pfizer, Dr. Habib was executive director of global business development for Organon Pharmaceuticals, a division of Akzo Nobel, where he was responsible for the identification, evaluation, and negotiation of in-licensing, out-licensing and divestiture opportunities in neuroscience, fertility, and women health. He started his career at Bristol-Myers Squibb where he spent nine years in various research, corporate, and business development roles including as director of corporate and business development. Dr. Habib holds a Ph.D. in pharmaceutical sciences from the University of Maryland and an M.B.A. with a major in finance and marketing from New York University Stern School of Business.
Michael W. Lark, Ph.D.
Senior Vice President, Research and Chief Scientific Officer
Dr. Lark joined Trevena as Senior VP and Head of Research in February 2008. Prior to this, he was Vice President of Biology at Centocor R&D where he was responsible for the therapeutic discovery strategy and execution in immunology, oncology, tissue remodeling and biomarkers. In this role, Dr. Lark managed a portfolio of approximately 15 drug discovery projects as well as supported the development of 14 new molecular entities (two in late stage clinical development) and one product. He was previously Director of Musculoskeletal Diseases at GlaxoSmithKline, where he managed a portfolio of drug discovery projects targeting osteoporosis, osteoarthritis, rheumatoid arthritis and psoriasis. Before joining SmithKline Beecham in 1996, Dr. Lark was a Senior Investigator at Merck Research laboratories, where he led a drug discovery team targeting matrix metalloproteinase-3 for the treatment of osteoarthritis. He has published over 115 peer reviewed papers, reviews and book chapters. Dr. Lark received his B.S. in Microbiology from the Pennsylvania State University and his Ph.D. in Molecular Biology and Microbiology from the Case Western Reserve University Medical School. He completed a postdoctoral fellowship in the Department of Pathology at The University of Washington.
John M. Limongelli, Esq.
Senior Vice President, General Counsel and Chief Administrative Officer
Mr. Limongelli joined Trevena as Senior Vice President, General Counsel & Corporate Secretary in May 2014 and became Chief Administrative Officer in March 2016. Prior to joining us, he was Vice President, Associate Chief Counsel and Corporate Secretary at Cigna Corporation. From 2008 to 2011, he served as Senior Vice President, General Counsel and Secretary at Adolor Corporation, a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain and pain management products. Prior to Adolor, Mr. Limongelli held roles of increasing responsibility with Cephalon, Inc., most recently serving as Vice President, Associate General Counsel & Secretary. Mr. Limongelli began his legal career in private practice with Morgan, Lewis & Bockius, LLP, in Philadelphia; he also later served as a partner with a local Philadelphia-area firm after the sale of Adolor to Cubist Pharmaceuticals. Prior to becoming an attorney, Mr. Limongelli was a certified public accountant and he worked as an auditor with KPMG LLP and as a financial analyst with Bell Atlantic Corp. Mr. Limongelli obtained both his J.D. and M.B.A. with honors from Temple University.
Copyright © Trevena, Inc.